Cortex-Based Startup Pairidex Closes Seed Round to Accelerate Commercial Launch of Personalized Leukemia Testing

Pairidex, a precision diagnostics company advancing personalized molecular testing for hematologic malignancies, today announced the successful close of its oversubscribed Seed financing round. The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™, the company's personalized, RNA-based laboratory developed test (LDT) for monitoring measurable residual disease (MRD) in fusion-driven blood cancers.

The financing marks a significant milestone for Pairidex as it transitions from product development to commercialization, positioning the company to address a substantial unmet need in precision oncology through highly sensitive, personalized MRD testing.